Baxter
Biosimilar developer, United States. 3 development products across 2 molecules: enoxaparin sodium, insulin human.
About Baxter
Baxter, the hospital products company, has two products that count as biosimilars only in Canada: Myxredlin, a ready-to-use intravenous human insulin, and Axberi, an enoxaparin. Myxredlin was approved as a drug in the United States and withdrawn in Europe without launch under the name Inpremzia.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Enoxaparin sodium | Axberi | · | · | · | · | Jul 2023 | · | · | 1/7 |
| Insulin human | Inpremzia | · | withdrawn | · | · | · | · | · | 0/7 |
| Insulin human | Myxredlin | · | · | · | · | Aug 2022 | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Baxter, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- HCAug 2022Myxredlin, insulin human
- HCJul 2023Axberi, enoxaparin sodium
Compare Baxter with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant